These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 25143023)

  • 1. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
    HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
    Vingerhoets J; Calvez V; Flandre P; Marcelin AG; Ceccherini-Silberstein F; Perno CF; Mercedes Santoro M; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Günthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M;
    HIV Med; 2015 May; 16(5):297-306. PubMed ID: 25585664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
    Hull MW; Montaner JS
    Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
    Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
    Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
    Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
    J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
    Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
    HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
    Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
    Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.